Arcutis’ ZORYVE Wins Marie Claire Beauty Award, Extending Dominance…

Event summary

Arcutis’ ZORYVE cream 0.15% won the inaugural 2026 Marie Claire Best Prescription Skin Solution Award for treating mild to moderate atopic dermatitis (eczema).
ZORYVE is the first prescription medication to win this award, highlighting innovation in medical dermatology.
ZORYVE is the top prescribed branded topical therapy for eczema, plaque psoriasis, and seborrheic dermatitis combined.
The award adds to ZORYVE’s previous accolades, including Allure’s 2025 Best of Beauty Breakthrough Award and Glamour’s 2024 Beauty and Wellness Award.
Simone Biles partnered with Arcutis to launch the Skin to Believe In campaign, raising awareness for chronic inflammatory skin diseases.

The big picture

Arcutis’ ZORYVE continues to solidify its position as a leader in dermatological treatments, with this latest award reinforcing its reputation for innovation. The recognition underscores the growing acceptance of prescription therapies in the skincare market, where medical and cosmetic solutions are increasingly converging. Arcutis’ ability to leverage such awards could further boost its market share in treating inflammatory skin conditions.

What we're watching

Market Leadership: Whether Arcutis can sustain ZORYVE’s dominance in the dermatology market amid growing competition.
Regulatory Approvals: The pace at which Arcutis advances its pipeline, particularly for new indications or formulations of ZORYVE.
Brand Awareness: How the partnership with Simone Biles impacts patient engagement and prescription rates for ZORYVE.